BUY Maruti Suzuki India Limited — Manas Jaiswal
byManas JaiswalHorizon: NA (inferred Swing (≤2wk))16 Jul 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·17 Jul · 3d ago
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·7 Jul · 2w ago
Maruti Suzuki India Ltd's new vehicle manufacturing facility in Kharkhoda has been inaugurated by the Prime Ministers of India and Japan, signaling significant expansion and production capacity.
BSE · Company Update·2 Jul · 2w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Maruti Suzuki India
- SELL — Amit Seth21 Oct 2026 · ~2 weeks · target ₹10,700 · Active
- BUY — Pradeep Haldar, PHD Capital21 Oct 2026 · ~1 year · target ₹16,500 · Active
- BUY — Rahul Sharma, JM Financial19 Oct 2026 · ~2 weeks · target ₹12,000 · Active
- BUY — Rajesh Satpute19 Oct 2026 · ~2 weeks · target ₹12,000 · SL hit
- BUY — Ashish Bahety, Profitmart Securities19 Oct 2026 · ~2 weeks · target ₹12,000 · SL hit
More from Manas Jaiswal
- BUY Ajanta Pharma23 Oct 2026 · Same day · target ₹3,425 · SL hit
- BUY Torrent Pharmaceuticals23 Oct 2026 · Same day · target ₹4,725 · SL hit
- BUY SAGILITY23 Oct 2026 · ~2 weeks · target ₹50 · SL hit
- BUY Zydus Lifesciences22 Oct 2026 · ~3 months · target ₹1,160 · SL hit
- BUY IPCA Laboratories22 Oct 2026 · ~2 weeks · target ₹2,000 · Active

